Aliases:This biomarker is also known as:
- 3-hydroxyacyl-CoA dehydrogenase type-2,
- amyloid-beta peptide binding alcohol dehydrogenase,
- 17-beta-HSD 10,
- 17-beta-hydroxysteroid dehydrogenase 10,
- Short-chain type dehydrogenase/reductase XH98G2,
- Endoplasmic reticulum-associated amyloid beta-peptide-binding protein,
- mitochondrial RNase P subunit 2,
- 3-hydroxyacyl-CoA dehydrogenase type II,
- Type II HADH,
- hydroxyacyl-Coenzyme A dehydrogenase, type II, hydroxyacyl-Coenzyme A dehydrogenase, type II,
- 3-hydroxy-2-methylbutyryl-CoA dehydrogenase,
- hydroxysteroid (17-beta) dehydrogenase 10,
- AB-binding alcohol dehydrogenase,
- short chain dehydrogenase/reductase family 5C, member 1,
- EC 184.108.40.206,EC 220.127.116.11,
- endoplasmic reticulum-associated amyloid beta-peptide-binding protein,
- Mitochondrial RNase P protein 2,
- short chain type dehydrogenase/reductase XH98G2,
- mental retardation, X-linked, syndromic 10,
- mitochondrial ribonuclease P protein 2,
- Mitochondrial ribonuclease P protein 2,
- short chain L-3-hydroxyacyl-CoA dehydrogenase type 2,
HSD17B10, hydroxysteroid (17-beta) dehydrogenase 10, is a member of the short-chain dehydrogenase/reductase superfamily. HSD17B10 functions in mitochondrial tRNA maturation and catalyzes the oxidation of a wide variety of fatty acids, alcohols, and steroids. The protein is thought to play a role in the development of Alzheimer's disease. There are several alternatively spliced transcript variants, of which only two have been fully sequenced.
There are no datasets associated with this biomarker.
The following organs have data associated with this biomarker…
|QA State:||Under Review|
No additional breast data is available.
HSD17B10 was one of numerous potential early detection biomarkers specific to triple-negative breast cancer in multiple pathways identified.